Further survival analysis using the clinical tumour biopsy samples demonstrated that neither IGFBP‐2 nor GRP78 expression were significantly associated with survival alone (IGFBP‐2, p = 0.395; GRP78, p = 0.509), despite 80.4% (74/92) patients displaying high GRP78 tumour expression and 81.5% (75/92) patients displaying high IGFBP‐2 tumour expression. The gene discussed is IGFBP2; the disease is neoplasm.